- Health Topics
- The Science
- Grants and Training
- News and Events
- About NHLBI
All News
|
Research Feature
A cell-based look at how the body responds to immune threats may one day help researchers find better treatments for this major U.S. killer For more than a decade, researchers have known that a core component of human immune function – called complement – can influence how the body responds to immune threats. Now researchers from the NIH and around...
Showing 10 out of 344 results
|
Media Availability
NIH-wide initiative details efforts to advance sleep and circadian biology research WHAT: The National Institutes of Health’s Sleep Research Plan outlines five goals and nine critical research opportunities to advance sleep and circadian biology research. Key features of the plan focus on studying sleep and circadian mechanisms that underlie health...
|
News Release
Researchers have linked a rare genetic mutation found mostly in Black Americans and other people of African descent to an earlier onset of heart failure and a higher risk of hospitalization. The findings suggest that earlier screening for the mutation could lead to faster treatment and improved outcomes for heart failure in this vulnerable group...
|
News Release
A small clinical trial supported by the National Institutes of Health has found that eating during the nighttime—like many shift workers do—can increase glucose levels, while eating only during the daytime might prevent the higher glucose levels now linked with a nocturnal work life. The findings, the study authors said, could lead to novel...
|
News Release
NIH-funded study finds better short-term outcomes, but increased need for a pacemaker Patients with mitral and tricuspid valve regurgitation, a condition sometimes called “leaky heart valves,” appeared to do better after two years if they had a tricuspid valve repair at the time of mitral valve surgery, according to a study supported by the...
|
Media Advisory
Hoy se anunció que el Dr. Pérez-Stable y el Dr. Gibbons fueron los ganadores de la medalla de Respuesta al COVID-19 y que aceptarán este premio en una gala esta noche en Washington, D. C. Los líderes de los NIH encabezan dos importantes programas federales: RADx-UP y la Alianza de participación comunitaria (CEAL) contra las disparidades causadas...
|
Media Advisory
Today, the Partnership for Public Service awarded a Samuel J. Heyman Service to America Medal (the Sammies) to Dr. Gary H. Gibbons, director, National Heart, Lung, and Blood Institute (NHLBI) and Dr. Eliseo J. Pérez-Stable, director, National Institute on Minority Health and Health Disparities (NIMHD). The two received the COVID-19 Response medal...
|
News Release
NIH-supported research suggests sleep patterns to support optimal health can begin in infancy Infants who sleep longer through the night and with fewer interruptions may be less likely to become overweight during their first six months of life, according to a study published in the journal SLEEP. While the research only showed a link – not a cause...
|
Media Advisory
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has announced April P. Carson, Ph.D., as the new director of the Jackson Heart Study (JHS). The JHS is the nation’s largest and longest-running longitudinal study of cardiovascular health in African Americans, involving more than 5,300 participants in...
|
News Release
The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City...
|
News Release
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due to lack of efficacy...